≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Thalassaemia

DOID EFO Endpoint Browser PheWeb

D3_THALASSAEMIA

Thalassemia: An inherited blood disorder characterized by a decreased synthesis of one of the polypeptide chains that form hemoglobin. Anemia results from this abnormal hemoglobin formation.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D56
  • Cause of death: ICD-10 — D56

2 out of 7 registries used, show all original rules.

-

4. Check minimum number of events

None

-

5. Include endpoints

145

6. Filter based on genotype QC (FinnGen only)

53

Control definitions (FinnGen only)

Control exclude
D3_HAEMOLYTICANAEMIA

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D55-D59
Name in latin
Thalassaemia

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 2202 1071 915
Only index persons 1582 880 702
Unadjusted period prevalence (%)
Whole population 0.05 0.03 0.03
Only index persons 0.03 0.03 0.03
Median age at first event (years)
Whole population 22.71 25.67 17.00
Only index persons 28.37 29.61 26.82

-FinnGen-

Key figures

All Female Male
Number of individuals 53 27 26
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 51.80 52.29 51.29

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
145
Matched controls
1450
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D56.0
ICD-10 Finland
Alpha thalassaemia
+∞
52.3
47
*
D56.3
ICD-10 Finland
Thalassaemia trait
+∞
42.9
39
*
D56.99
ICD-10 Finland
Thalassaemia, unspecified
+∞
37.1
34
*
D56.1
ICD-10 Finland
Beta thalassaemia
+∞
31.4
29
*
D56.91
ICD-10 Finland
Thalassemia minor
+∞
29.1
27
*
Z31.5
ICD-10 Finland
Genetic counselling
7.5
20.0
33
55
D64.9
ICD-10 Finland
Anaemia, unspecified
5.9
14.8
30
61
D56.2
ICD-10 Finland
Delta-beta thalassaemia
+∞
13.8
13
*
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
6.2
13.3
25
47
D56
ICD-10 Finland
Thalassaemia
+∞
11.6
11
*
O99.0
ICD-10 Finland
Anaemia complicating pregnancy, childbirth and the puerperium
19.8
11.0
16
9
R5430
NOMESCO Finland
Interpreter's services
59.1
9.8
11
*
D01
ICPC
Abdominal pain/cramps general
3.4
8.6
38
138
O99.1
ICD-10 Finland
Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating pregnancy, childbirth and the puerperium
95.4
8.5
9
*
D50.8
ICD-10 Finland
Other iron deficiency anaemias
35.5
8.2
10
*
D56.8
ICD-10 Finland
Other thalassaemias
+∞
7.3
7
*
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
3.4
6.8
27
91
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.9
6.7
21
60
D02
ICPC
Abdominal pain epigastric
4.5
6.6
17
42
A02BD07
ATC
lansoprazole, amoxicillin and clarithromycin; systemic
6.8
6.4
15
24

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
1.1e+00
2.1e+00
2.8e+00
—
2.6e+00
1.3e+00
9.6e-01
cases:20.90%
controls:8.36%
cases:30.88%
controls:5.27%
cases:9.56%
controls:0.67%
—
—
cases:7.35%
controls:0.59%
cases:17.16%
controls:5.26%
cases:32.48%
controls:15.55%
28
111
106
1216
42
71
94
1276
13
9
123
1338
—
10
8
126
1337
23
70
111
1261
38
183
79
994
Hematology
82 [38004501]
—
3.3e+00
—
1.0e+50
—
3.4e+00
3.1e+00
—
—
cases:8.82%
controls:0.37%
—
—
cases:13.97%
controls:0.00%
—
—
cases:10.45%
controls:0.38%
cases:10.26%
controls:0.51%
—
12
5
124
1342
—
19
0
117
1347
—
14
5
120
1326
12
6
105
1171
Outpatient Visit
OP [9202]
3.3e-01
8.6e-01
1.0e+00
5.1e+00
1.1e+00
9.3e-01
7.9e-01
cases:72.39%
controls:65.41%
cases:66.18%
controls:45.29%
cases:25.00%
controls:10.62%
cases:52.21%
controls:0.67%
cases:26.47%
controls:10.48%
cases:67.16%
controls:44.55%
cases:85.47%
controls:72.81%
97
868
37
459
90
610
46
737
34
143
102
1204
71
9
65
1338
36
141
100
1204
90
593
44
738
100
857
17
320
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
1.4e+00
2.6e+00
—
—
—
2.1e+00
2.0e+00
cases:7.46%
controls:1.88%
cases:12.50%
controls:1.04%
—
—
—
—
—
—
cases:6.72%
controls:0.90%
cases:11.97%
controls:1.87%
10
25
124
1302
17
14
119
1333
—
—
—
9
12
125
1319
14
22
103
1155
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
4.2e-01
1.0e+00
1.5e+00
2.2e+00
1.3e+00
7.7e-01
4.3e-01
cases:27.61%
controls:19.97%
cases:31.62%
controls:14.18%
cases:13.97%
controls:3.64%
cases:4.41%
controls:0.52%
cases:9.56%
controls:2.68%
cases:26.12%
controls:14.05%
cases:39.32%
controls:29.57%
37
265
97
1062
43
191
93
1156
19
49
117
1298
6
7
130
1340
13
36
123
1309
35
187
99
1144
46
348
71
829
Platelets [#/volume] in Blood
26515-7 [3007461]
3.1e-01
8.6e-01
1.3e+00
2.6e+00
1.5e+00
5.9e-01
2.3e-01
cases:36.57%
controls:29.77%
cases:41.18%
controls:22.79%
cases:16.18%
controls:4.83%
cases:6.62%
controls:0.52%
cases:15.44%
controls:4.09%
cases:35.07%
controls:23.07%
cases:50.43%
controls:44.77%
49
395
85
932
56
307
80
1040
22
65
114
1282
9
7
127
1340
21
55
115
1290
47
307
87
1024
59
527
58
650
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
1.7e+00
2.3e+00
—
—
—
2.3e+00
2.2e+00
cases:5.97%
controls:1.13%
cases:3.68%
controls:0.37%
—
—
—
—
—
—
cases:4.48%
controls:0.45%
cases:8.55%
controls:1.02%
8
15
126
1312
5
5
131
1342
—
—
—
6
6
128
1325
10
12
107
1165
MCH [Entitic mass]
28539-5 [3035941]
3.0e-01
8.7e-01
1.3e+00
2.6e+00
1.5e+00
5.9e-01
2.3e-01
cases:36.57%
controls:29.84%
cases:41.18%
controls:22.72%
cases:16.18%
controls:4.90%
cases:6.62%
controls:0.52%
cases:15.44%
controls:4.09%
cases:35.07%
controls:22.99%
cases:50.43%
controls:44.77%
49
396
85
931
56
306
80
1041
22
66
114
1281
9
7
127
1340
21
55
115
1290
47
306
87
1025
59
527
58
650
Leukocytes [#/volume] in Blood
26464-8 [3010813]
3.0e-01
8.6e-01
1.3e+00
2.6e+00
1.5e+00
6.2e-01
2.3e-01
cases:36.57%
controls:29.99%
cases:41.18%
controls:22.79%
cases:16.18%
controls:4.90%
cases:6.62%
controls:0.52%
cases:15.44%
controls:4.09%
cases:35.82%
controls:23.14%
cases:50.43%
controls:44.60%
49
398
85
929
56
307
80
1040
22
66
114
1281
9
7
127
1340
21
55
115
1290
48
308
86
1023
59
525
58
652
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
3.0e-01
8.6e-01
1.3e+00
2.6e+00
1.5e+00
5.9e-01
2.3e-01
cases:36.57%
controls:29.92%
cases:41.18%
controls:22.79%
cases:16.18%
controls:4.90%
cases:6.62%
controls:0.52%
cases:15.44%
controls:4.09%
cases:35.07%
controls:23.07%
cases:50.43%
controls:44.77%
49
397
85
930
56
307
80
1040
22
66
114
1281
9
7
127
1340
21
55
115
1290
47
307
87
1024
59
527
58
650
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
3.0e-01
8.6e-01
1.3e+00
2.6e+00
1.5e+00
5.9e-01
2.3e-01
cases:36.57%
controls:29.92%
cases:41.18%
controls:22.79%
cases:16.18%
controls:4.90%
cases:6.62%
controls:0.52%
cases:15.44%
controls:4.09%
cases:35.07%
controls:23.07%
cases:50.43%
controls:44.77%
49
397
85
930
56
307
80
1040
22
66
114
1281
9
7
127
1340
21
55
115
1290
47
307
87
1024
59
527
58
650
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
3.0e-01
8.6e-01
1.3e+00
2.6e+00
1.5e+00
5.8e-01
2.2e-01
cases:36.57%
controls:29.92%
cases:41.18%
controls:22.79%
cases:16.18%
controls:4.90%
cases:6.62%
controls:0.52%
cases:15.44%
controls:4.09%
cases:35.07%
controls:23.14%
cases:50.43%
controls:44.86%
49
397
85
930
56
307
80
1040
22
66
114
1281
9
7
127
1340
21
55
115
1290
47
308
87
1023
59
528
58
649
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
3.0e-01
8.6e-01
1.3e+00
2.6e+00
1.5e+00
5.9e-01
2.3e-01
cases:36.57%
controls:29.92%
cases:41.18%
controls:22.79%
cases:16.18%
controls:4.90%
cases:6.62%
controls:0.52%
cases:15.44%
controls:4.09%
cases:35.07%
controls:23.07%
cases:50.43%
controls:44.77%
49
397
85
930
56
307
80
1040
22
66
114
1281
9
7
127
1340
21
55
115
1290
47
307
87
1024
59
527
58
650
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.8e-01
1.1e+00
1.1e+00
2.3e+00
1.6e+00
8.5e-01
5.0e-01
cases:28.36%
controls:22.98%
cases:30.15%
controls:12.99%
cases:8.09%
controls:2.82%
cases:4.41%
controls:0.45%
cases:8.82%
controls:2.01%
cases:25.37%
controls:12.70%
cases:44.44%
controls:32.71%
38
305
96
1022
41
175
95
1172
11
38
125
1309
6
6
130
1341
12
27
124
1318
34
169
100
1162
52
385
65
792
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
1.5e+00
2.3e+00
—
—
—
1.9e+00
1.6e+00
cases:5.97%
controls:1.36%
cases:9.56%
controls:1.04%
—
—
—
—
—
—
cases:5.22%
controls:0.83%
cases:11.11%
controls:2.55%
8
18
126
1309
13
14
123
1333
—
—
—
7
11
127
1320
13
30
104
1147
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
1.4e+00
2.3e+00
—
—
—
1.9e+00
1.5e+00
cases:5.97%
controls:1.51%
cases:9.56%
controls:1.04%
—
—
—
—
—
—
cases:5.22%
controls:0.83%
cases:11.97%
controls:2.89%
8
20
126
1307
13
14
123
1333
—
—
—
7
11
127
1320
14
34
103
1143
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
1.4e+00
2.1e+00
—
—
—
1.8e+00
1.3e+00
cases:6.72%
controls:1.81%
cases:9.56%
controls:1.34%
—
—
—
—
—
—
cases:5.97%
controls:1.05%
cases:11.11%
controls:3.14%
9
24
125
1303
13
18
123
1329
—
—
—
8
14
126
1317
13
37
104
1140
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
1.5e+00
2.4e+00
—
—
—
1.4e+00
1.3e+00
cases:16.42%
controls:4.22%
cases:19.12%
controls:2.08%
—
—
—
—
—
—
cases:6.72%
controls:1.80%
cases:17.95%
controls:5.78%
22
56
112
1271
26
28
110
1319
—
—
—
9
24
125
1307
21
68
96
1109
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
2.5e+00
—
—
—
—
—
2.7e+00
cases:5.22%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:6.84%
controls:0.51%
7
6
127
1321
—
—
—
—
—
8
6
109
1171
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
3.2e-03
1.2e+00
1.5e+00
—
1.7e+00
1.1e+00
1.1e+00
cases:11.94%
controls:11.91%
cases:18.38%
controls:6.16%
cases:5.88%
controls:1.34%
—
—
cases:6.62%
controls:1.34%
cases:15.67%
controls:5.56%
cases:31.62%
controls:13.85%
16
158
118
1169
25
83
111
1264
8
18
128
1329
—
9
18
127
1327
21
74
113
1257
37
163
80
1014
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
1.4e+00
2.8e+00
—
—
—
2.1e+00
2.2e+00
cases:3.73%
controls:0.98%
cases:6.62%
controls:0.45%
—
—
—
—
—
—
cases:3.73%
controls:0.45%
cases:11.97%
controls:1.44%
5
13
129
1314
9
6
127
1341
—
—
—
5
6
129
1325
14
17
103
1160
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
—
2.5e+00
—
1.0e+50
—
2.2e+00
—
—
—
cases:6.62%
controls:0.59%
—
—
cases:11.76%
controls:0.00%
—
—
cases:5.97%
controls:0.68%
—
—
—
9
8
127
1339
—
16
0
120
1347
—
8
9
126
1322
—
Laboratory Visit
OMOP4822461 [32036]
7.0e-02
4.3e-01
9.7e-01
2.7e+00
9.9e-01
3.1e-01
7.4e-02
cases:36.57%
controls:34.97%
cases:41.91%
controls:32.00%
cases:21.32%
controls:9.28%
cases:8.09%
controls:0.59%
cases:19.12%
controls:8.10%
cases:41.04%
controls:33.81%
cases:52.99%
controls:51.15%
49
464
85
863
57
431
79
916
29
125
107
1222
11
8
125
1339
26
109
110
1236
55
450
79
881
62
602
55
575
CBC panel - Blood by Automated count
58410-2 [40761511]
1.6e-01
7.4e-01
1.4e+00
2.3e+00
1.7e+00
7.7e-01
1.4e-01
cases:29.10%
controls:25.92%
cases:28.68%
controls:16.04%
cases:11.03%
controls:3.04%
cases:3.68%
controls:0.37%
cases:11.03%
controls:2.16%
cases:26.87%
controls:14.58%
cases:39.32%
controls:35.94%
39
344
95
983
39
216
97
1131
15
41
121
1306
5
5
131
1342
15
29
121
1316
36
194
98
1137
46
423
71
754
Internal Medicine
11 [38004456]
4.4e-01
1.2e+00
9.3e-01
—
1.5e+00
9.9e-01
7.5e-01
cases:23.13%
controls:16.28%
cases:19.12%
controls:6.76%
cases:3.68%
controls:1.48%
—
—
cases:6.62%
controls:1.49%
cases:15.67%
controls:6.46%
cases:27.35%
controls:15.04%
31
216
103
1111
26
91
110
1256
5
20
131
1327
—
9
20
127
1325
21
86
113
1245
32
177
85
1000
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
1.1e+00
2.1e+00
-1.0e+50
—
—
8.9e-01
1.2e+00
cases:11.94%
controls:4.14%
cases:11.03%
controls:1.56%
cases:0.00%
controls:0.37%
—
—
—
—
cases:4.48%
controls:1.88%
cases:19.66%
controls:6.80%
16
55
118
1272
15
21
121
1326
0
5
136
1342
—
—
6
25
128
1306
23
80
94
1097
Eosinophils [#/volume] in Blood
26449-9 [3013115]
1.2e-01
1.3e+00
1.5e+00
—
1.8e+00
8.1e-01
9.4e-01
cases:11.19%
controls:10.02%
cases:16.91%
controls:5.12%
cases:3.68%
controls:0.82%
—
—
cases:5.15%
controls:0.89%
cases:11.94%
controls:5.71%
cases:29.06%
controls:13.85%
15
133
119
1194
23
69
113
1278
5
11
131
1336
—
7
12
129
1333
16
76
118
1255
34
163
83
1014
Case Management Agency
251B00000X [38004193]
-1.1e-02
2.9e-01
3.9e-01
2.9e+00
8.0e-01
3.0e-01
1.0e-01
cases:58.21%
controls:58.48%
cases:57.35%
controls:50.11%
cases:27.94%
controls:20.86%
cases:27.21%
controls:2.00%
cases:33.82%
controls:18.74%
cases:58.96%
controls:51.62%
cases:75.21%
controls:73.24%
78
776
56
551
78
675
58
672
38
281
98
1066
37
27
99
1320
46
252
90
1093
79
687
55
644
88
862
29
315
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
4.3e-01
1.1e+00
—
—
1.9e+00
1.5e+00
1.1e+00
cases:9.70%
controls:6.56%
cases:10.29%
controls:3.71%
—
—
—
—
cases:4.41%
controls:0.67%
cases:11.94%
controls:3.08%
cases:24.79%
controls:9.60%
13
87
121
1240
14
50
122
1297
—
—
6
9
130
1336
16
41
118
1290
29
113
88
1064
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.4e-01
9.2e-01
9.4e-01
2.5e+00
1.1e+00
6.2e-01
2.7e-01
cases:25.37%
controls:21.02%
cases:27.94%
controls:13.44%
cases:5.88%
controls:2.38%
cases:4.41%
controls:0.37%
cases:6.62%
controls:2.23%
cases:23.13%
controls:13.90%
cases:37.61%
controls:31.52%
34
279
100
1048
38
181
98
1166
8
32
128
1315
6
5
130
1342
9
30
127
1315
31
185
103
1146
44
371
73
806
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.5e-01
9.1e-01
9.4e-01
2.5e+00
1.1e+00
6.4e-01
2.3e-01
cases:25.37%
controls:20.95%
cases:27.94%
controls:13.51%
cases:5.88%
controls:2.38%
cases:4.41%
controls:0.37%
cases:6.62%
controls:2.30%
cases:23.13%
controls:13.75%
cases:36.75%
controls:31.69%
34
278
100
1049
38
182
98
1165
8
32
128
1315
6
5
130
1342
9
31
127
1314
31
183
103
1148
43
373
74
804
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
3.5e-01
8.2e-01
1.2e+00
2.5e+00
1.1e+00
4.8e-01
1.9e-01
cases:30.60%
controls:23.66%
cases:31.62%
controls:16.93%
cases:8.82%
controls:2.97%
cases:4.41%
controls:0.37%
cases:8.82%
controls:3.12%
cases:25.37%
controls:17.36%
cases:41.88%
controls:37.30%
41
314
93
1013
43
228
93
1119
12
40
124
1307
6
5
130
1342
12
42
124
1303
34
231
100
1100
49
439
68
738
Carpal tunnel syndrome
G56.0 [45566891]
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.97%
controls:0.38%
—
—
—
—
—
—
—
8
5
126
1326
—
Helicobacter pylori Ag [Presence] in Stool
31843-6 [3013139]
2.8e+00
—
—
—
—
—
—
cases:6.72%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
9
6
125
1321
—
—
—
—
—
—
Anaemia, unspecified
D64.9 [45600610]
2.7e+00
—
—
—
—
—
1.8e+00
cases:5.22%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.76%
7
5
127
1322
—
—
—
—
—
5
9
112
1168
poliomyelitis, trivalent, inactivated, whole virus
J07BF03 [21601352]
2.7e+00
—
—
—
—
—
—
cases:5.22%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
7
5
127
1322
—
—
—
—
—
—
calcium (different salts in combination); oral
A12AA20 [21600872]
6.6e-01
9.8e-01
—
—
—
1.3e+00
1.3e+00
cases:7.46%
controls:3.99%
cases:8.09%
controls:3.19%
—
—
—
—
—
—
cases:9.70%
controls:2.78%
cases:17.95%
controls:5.69%
10
53
124
1274
11
43
125
1304
—
—
—
13
37
121
1294
21
67
96
1110
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
1.3e+00
—
—
—
—
1.6e+00
1.4e+00
cases:8.96%
controls:2.71%
—
—
—
—
—
—
—
—
cases:4.48%
controls:0.90%
cases:11.97%
controls:3.40%
12
36
122
1291
—
—
—
—
6
12
128
1319
14
40
103
1137
Emergency Room Visit
ER [9203]
4.3e-01
8.8e-01
—
—
1.1e+00
9.2e-01
8.0e-01
cases:44.03%
controls:33.84%
cases:25.00%
controls:12.10%
—
—
—
—
cases:4.41%
controls:1.56%
cases:23.13%
controls:10.74%
cases:46.15%
controls:27.78%
59
449
75
878
34
163
102
1184
—
—
6
21
130
1324
31
143
103
1188
54
327
63
850
Supplier / Service Provider
OMOP5117446 [33004]
-9.2e-01
-3.5e-01
—
—
—
—
3.5e+00
cases:12.69%
controls:26.68%
cases:5.88%
controls:8.17%
—
—
—
—
—
—
—
—
cases:18.80%
controls:0.68%
17
354
117
973
8
110
128
1237
—
—
—
—
22
8
95
1169
Differential panel, method unspecified - Blood
69738-3 [42870588]
5.3e-01
1.3e+00
—
—
1.5e+00
9.9e-01
1.3e+00
cases:9.70%
controls:5.95%
cases:10.29%
controls:3.12%
—
—
—
—
cases:3.68%
controls:0.82%
cases:9.70%
controls:3.83%
cases:23.93%
controls:7.82%
13
79
121
1248
14
42
122
1305
—
—
5
11
131
1334
13
51
121
1280
28
92
89
1085
ferrous glycine sulfate; oral
B03AA01 [21601080]
2.5e+00
—
—
—
—
—
—
cases:4.48%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
128
1322
—
—
—
—
—
—
INR in Blood by Coagulation assay
34714-6 [3032080]
-9.4e-02
9.7e-01
—
—
—
1.5e+00
1.0e+00
cases:4.48%
controls:4.90%
cases:5.15%
controls:2.00%
—
—
—
—
—
—
cases:8.21%
controls:2.03%
cases:15.38%
controls:6.03%
6
65
128
1262
7
27
129
1320
—
—
—
11
27
123
1304
18
71
99
1106
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.3e-01
1.3e+00
—
—
1.7e+00
7.7e-01
1.1e+00
cases:10.45%
controls:9.27%
cases:15.44%
controls:4.83%
—
—
—
—
cases:4.41%
controls:0.82%
cases:10.45%
controls:5.11%
cases:29.06%
controls:12.06%
14
123
120
1204
21
65
115
1282
—
—
6
11
130
1334
14
68
120
1263
34
142
83
1035
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.6e-01
1.3e+00
—
—
1.7e+00
7.7e-01
1.1e+00
cases:10.45%
controls:9.04%
cases:15.44%
controls:4.75%
—
—
—
—
cases:4.41%
controls:0.82%
cases:10.45%
controls:5.11%
cases:28.21%
controls:11.98%
14
120
120
1207
21
64
115
1283
—
—
6
11
130
1334
14
68
120
1263
33
141
84
1036
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.6e-01
1.3e+00
—
—
1.7e+00
7.9e-01
1.1e+00
cases:10.45%
controls:9.04%
cases:15.44%
controls:4.75%
—
—
—
—
cases:4.41%
controls:0.82%
cases:10.45%
controls:5.03%
cases:28.21%
controls:11.98%
14
120
120
1207
21
64
115
1283
—
—
6
11
130
1334
14
67
120
1264
33
141
84
1036
Ultrasound examination of mammary glands
HA1AE [2001303886]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.42%
—
—
—
—
—
—
5
5
112
1172
Fever, unspecified
R50.9 [45582716]
1.0e+00
—
—
—
—
2.3e+00
—
cases:4.48%
controls:1.66%
—
—
—
—
—
—
—
—
cases:4.48%
controls:0.45%
—
—
6
22
128
1305
—
—
—
—
6
6
128
1325
—
Pharmacy visit
OMOP4822462 [581458]
-6.0e-01
4.1e-01
5.0e-02
2.3e+00
4.4e-01
4.2e-01
7.0e-01
cases:88.06%
controls:93.07%
cases:83.82%
controls:77.43%
cases:36.03%
controls:34.89%
cases:8.82%
controls:0.97%
cases:45.59%
controls:35.02%
cases:85.07%
controls:78.96%
cases:96.58%
controls:93.37%
118
1235
16
92
114
1043
22
304
49
470
87
877
12
13
124
1334
62
471
74
874
114
1051
20
280
113
1099
4
78
ABO and Rh group [Type] in Blood
882-1 [3003694]
4.0e-01
1.3e+00
—
—
-1.0e+50
—
9.7e-01
cases:8.21%
controls:5.65%
cases:8.82%
controls:2.52%
—
—
—
—
cases:0.00%
controls:0.45%
—
—
cases:15.38%
controls:6.46%
11
75
123
1252
12
34
124
1313
—
—
0
6
136
1339
—
18
76
99
1101
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
3.7e-01
9.0e-01
1.4e+00
—
1.1e+00
6.6e-01
8.3e-02
cases:29.85%
controls:22.76%
cases:31.62%
controls:15.89%
cases:11.76%
controls:3.34%
—
—
cases:8.82%
controls:3.05%
cases:26.87%
controls:15.93%
cases:36.75%
controls:34.83%
40
302
94
1025
43
214
93
1133
16
45
120
1302
—
12
41
124
1304
36
212
98
1119
43
410
74
767
Monocytes [#/volume] in Blood
26484-6 [3001604]
9.7e-02
1.3e+00
1.6e+00
—
1.6e+00
8.3e-01
9.2e-01
cases:10.45%
controls:9.57%
cases:16.18%
controls:5.05%
cases:3.68%
controls:0.74%
—
—
cases:4.41%
controls:0.89%
cases:11.94%
controls:5.56%
cases:28.21%
controls:13.51%
14
127
120
1200
22
68
114
1279
5
10
131
1337
—
6
12
130
1333
16
74
118
1257
33
159
84
1018
Basophils [#/volume] in Blood
26444-0 [3006315]
1.1e-01
1.3e+00
1.6e+00
—
1.6e+00
8.3e-01
9.2e-01
cases:10.45%
controls:9.50%
cases:16.18%
controls:5.05%
cases:3.68%
controls:0.74%
—
—
cases:4.41%
controls:0.89%
cases:11.94%
controls:5.56%
cases:28.21%
controls:13.51%
14
126
120
1201
22
68
114
1279
5
10
131
1337
—
6
12
130
1333
16
74
118
1257
33
159
84
1018
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
6.3e-02
1.2e+00
—
—
1.5e+00
8.4e-01
1.0e+00
cases:10.45%
controls:9.87%
cases:15.44%
controls:5.20%
—
—
—
—
cases:3.68%
controls:0.82%
cases:11.19%
controls:5.18%
cases:28.21%
controls:12.66%
14
131
120
1196
21
70
115
1277
—
—
5
11
131
1334
15
69
119
1262
33
149
84
1028
FEV1 percent change
69983-5 [42868472]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:0.59%
—
—
—
—
—
—
6
7
111
1170
FEV1/FVC --post bronchodilation
69970-2 [42868459]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:0.59%
—
—
—
—
—
—
6
7
111
1170
FEV1 --post bronchodilation
20155-8 [3023550]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:0.59%
—
—
—
—
—
—
6
7
111
1170
FVC percent change Respiratory system
69982-7 [42868471]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:0.59%
—
—
—
—
—
—
6
7
111
1170
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:0.59%
—
—
—
—
—
—
6
7
111
1170
Hand Surgery
40 [38004480]
—
—
—
1.0e+50
—
2.2e+00
7.6e-01
—
—
—
—
—
—
cases:5.15%
controls:0.00%
—
—
cases:4.48%
controls:0.53%
cases:5.13%
controls:2.46%
—
—
—
7
0
129
1347
—
6
7
128
1324
6
29
111
1148
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
6.3e-02
1.2e+00
—
—
1.5e+00
8.2e-01
9.7e-01
cases:10.45%
controls:9.87%
cases:15.44%
controls:5.27%
—
—
—
—
cases:3.68%
controls:0.82%
cases:11.19%
controls:5.26%
cases:28.21%
controls:12.91%
14
131
120
1196
21
71
115
1276
—
—
5
11
131
1334
15
70
119
1261
33
152
84
1025
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
-2.9e-03
1.2e+00
—
—
1.6e+00
9.0e-01
9.1e-01
cases:10.45%
controls:10.47%
cases:16.18%
controls:5.42%
—
—
—
—
cases:4.41%
controls:0.97%
cases:12.69%
controls:5.56%
cases:28.21%
controls:13.68%
14
139
120
1188
22
73
114
1274
—
—
6
13
130
1332
17
74
117
1257
33
161
84
1016
FEV1
20150-9 [3024653]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:0.68%
—
—
—
—
—
—
6
8
111
1169
Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] in Blood
88518-6 [36304997]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:0.68%
—
—
—
—
—
—
6
8
111
1169
FEV1/FVC
19926-5 [3011505]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:0.68%
—
—
—
—
—
—
6
8
111
1169
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:0.68%
—
—
—
—
—
—
6
8
111
1169
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
4.5e-01
2.1e+00
—
—
—
—
1.1e+00
cases:3.73%
controls:2.41%
cases:6.62%
controls:0.89%
—
—
—
—
—
—
—
—
cases:6.84%
controls:2.29%
5
32
129
1295
9
12
127
1335
—
—
—
—
8
27
109
1150
pantoprazole; oral, parenteral
A02BC02 [21600097]
8.0e-01
8.8e-01
—
—
—
1.2e+00
6.4e-01
cases:20.90%
controls:10.63%
cases:11.03%
controls:4.90%
—
—
—
—
—
—
cases:14.93%
controls:4.81%
cases:23.93%
controls:14.19%
28
141
106
1186
15
66
121
1281
—
—
—
20
64
114
1267
28
167
89
1010
Dorsalgia
M54 [45553203]
—
-1.0e+50
—
—
—
—
2.0e+00
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:6.84%
controls:1.02%
—
0
6
136
1341
—
—
—
—
8
12
109
1165
Normoblasts [#/volume] in Blood
715-3 [3021589]
1.1e-01
9.0e-01
1.3e+00
—
1.5e+00
9.8e-01
7.8e-01
cases:8.96%
controls:8.06%
cases:14.71%
controls:6.53%
cases:5.15%
controls:1.41%
—
—
cases:5.15%
controls:1.19%
cases:13.43%
controls:5.48%
cases:21.37%
controls:11.05%
12
107
122
1220
20
88
116
1259
7
19
129
1328
—
7
16
129
1329
18
73
116
1258
25
130
92
1047
rubella, live attenuated
J07BJ01 [21601359]
1.9e+00
—
—
—
—
—
—
cases:5.22%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
127
1316
—
—
—
—
—
—
Pregnancy
W78 [2002001269]
-3.7e-02
1.1e+00
1.9e+00
—
—
6.9e-01
6.2e-01
cases:5.97%
controls:6.18%
cases:8.82%
controls:3.19%
cases:5.88%
controls:0.97%
—
—
—
—
cases:5.97%
controls:3.08%
cases:9.40%
controls:5.27%
8
82
126
1245
12
43
124
1304
8
13
128
1334
—
—
8
41
126
1290
11
62
106
1115
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2.9e-01
1.8e+00
—
—
—
1.2e+00
6.3e-01
cases:5.97%
controls:4.52%
cases:6.62%
controls:1.11%
—
—
—
—
—
—
cases:3.73%
controls:1.20%
cases:7.69%
controls:4.25%
8
60
126
1267
9
15
127
1332
—
—
—
5
16
129
1315
9
50
108
1127
pH of Serum or Plasma
2753-2 [3018418]
7.6e-01
1.8e+00
—
—
—
9.8e-01
5.9e-01
cases:7.46%
controls:3.62%
cases:7.35%
controls:1.26%
—
—
—
—
—
—
cases:3.73%
controls:1.43%
cases:8.55%
controls:4.93%
10
48
124
1279
10
17
126
1330
—
—
—
5
19
129
1312
10
58
107
1119
Abdominal pain/cramps general
D01 [2002000300]
1.8e+00
—
—
—
—
—
1.3e+00
cases:8.96%
controls:1.58%
—
—
—
—
—
—
—
—
—
—
cases:6.84%
controls:2.04%
12
21
122
1306
—
—
—
—
—
8
24
109
1153
Laboratory test
15220000 [4034850]
—
—
—
—
—
1.8e+00
2.4e-01
—
—
—
—
—
—
—
—
—
—
cases:5.22%
controls:0.90%
cases:4.27%
controls:3.40%
—
—
—
—
—
7
12
127
1319
5
40
112
1137
Shoulder symptom/complaint
L08 [2002000632]
1.8e+00
—
—
—
—
-1.0e+50
1.0e+00
cases:5.22%
controls:0.90%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:5.98%
controls:2.29%
7
12
127
1315
—
—
—
—
0
8
134
1323
7
27
110
1150
Pain localized to upper abdomen
R10.1 [45568111]
1.7e+00
—
—
—
—
—
1.2e+00
cases:8.96%
controls:1.73%
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:1.53%
12
23
122
1304
—
—
—
—
—
6
18
111
1159
Inpatient Hospital
21 [8717]
1.5e-01
5.6e-01
—
—
1.2e+00
8.5e-01
8.6e-01
cases:35.82%
controls:32.48%
cases:17.65%
controls:10.91%
—
—
—
—
cases:3.68%
controls:1.12%
cases:20.15%
controls:9.77%
cases:43.59%
controls:24.55%
48
431
86
896
24
147
112
1200
—
—
5
15
131
1330
27
130
107
1201
51
289
66
888
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.5e-01
7.6e-01
1.7e+00
—
1.1e+00
4.9e-01
4.8e-01
cases:20.90%
controls:15.75%
cases:21.32%
controls:11.28%
cases:6.62%
controls:1.34%
—
—
cases:5.15%
controls:1.86%
cases:16.42%
controls:10.74%
cases:35.04%
controls:25.06%
28
209
106
1118
29
152
107
1195
9
18
127
1329
—
7
25
129
1320
22
143
112
1188
41
295
76
882
folic acid
V04CX02 [715877]
—
2.3e+00
—
—
—
1.7e+00
1.6e+00
—
—
cases:3.68%
controls:0.37%
—
—
—
—
—
—
cases:4.48%
controls:0.83%
cases:8.55%
controls:1.78%
—
5
5
131
1342
—
—
—
6
11
128
1320
10
21
107
1156
folic acid; oral, parenteral
B03BB01 [21601129]
—
2.3e+00
—
—
—
1.7e+00
1.6e+00
—
—
cases:3.68%
controls:0.37%
—
—
—
—
—
—
cases:4.48%
controls:0.83%
cases:8.55%
controls:1.78%
—
5
5
131
1342
—
—
—
6
11
128
1320
10
21
107
1156
Cathetrisation of vein
TPH04 [2001309597]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.55%
controls:1.87%
—
—
—
—
—
—
10
22
107
1155
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
4.3e-01
1.5e+00
—
—
—
8.5e-01
-2.6e-01
cases:5.22%
controls:3.47%
cases:7.35%
controls:1.71%
—
—
—
—
—
—
cases:4.48%
controls:1.95%
cases:5.13%
controls:6.54%
7
46
127
1281
10
23
126
1324
—
—
—
6
26
128
1305
6
77
111
1100
Chronic apical periodontitis
K04.5 [45586691]
1.5e+00
—
—
—
—
—
1.0e+00
cases:7.46%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
cases:6.84%
controls:2.55%
10
24
124
1303
—
—
—
—
—
8
30
109
1147
Weakness/tiredness general
A04 [2002000145]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.26%
controls:2.55%
—
—
—
—
—
—
12
30
105
1147
Thorax X-ray examination
GD1AA [2001303617]
4.8e-01
1.1e+00
—
—
—
1.3e+00
1.4e+00
cases:8.96%
controls:5.73%
cases:6.62%
controls:2.30%
—
—
—
—
—
—
cases:5.22%
controls:1.43%
cases:16.24%
controls:4.59%
12
76
122
1251
9
31
127
1316
—
—
—
7
19
127
1312
19
54
98
1123
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
4.7e-01
1.4e+00
-1.0e+50
—
—
8.0e-01
7.3e-01
cases:10.45%
controls:6.78%
cases:10.29%
controls:2.82%
cases:0.00%
controls:0.97%
—
—
—
—
cases:5.97%
controls:2.78%
cases:14.53%
controls:7.56%
14
90
120
1237
14
38
122
1309
0
13
136
1334
—
—
8
37
126
1294
17
89
100
1088
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
-3.1e-02
—
-1.0e+50
—
—
1.1e+00
1.4e+00
cases:3.73%
controls:3.84%
—
—
cases:0.00%
controls:0.45%
—
—
—
—
cases:4.48%
controls:1.50%
cases:14.53%
controls:4.16%
5
51
129
1276
—
0
6
136
1341
—
—
6
20
128
1311
17
49
100
1128
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
1.2e+00
1.9e+00
—
—
—
—
1.4e+00
cases:4.48%
controls:1.36%
cases:4.41%
controls:0.67%
—
—
—
—
—
—
—
—
cases:11.97%
controls:3.40%
6
18
128
1309
6
9
130
1338
—
—
—
—
14
40
103
1137
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
6.4e-01
—
—
—
—
1.1e+00
1.3e+00
cases:5.97%
controls:3.24%
—
—
—
—
—
—
—
—
cases:4.48%
controls:1.50%
cases:13.68%
controls:3.99%
8
43
126
1284
—
—
—
—
6
20
128
1311
16
47
101
1130
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
4.5e-01
1.3e+00
—
—
—
—
5.6e-01
cases:7.46%
controls:4.90%
cases:11.76%
controls:3.41%
—
—
—
—
—
—
—
—
cases:17.09%
controls:10.54%
10
65
124
1262
16
46
120
1301
—
—
—
—
20
124
97
1053
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
7.0e-01
8.9e-01
—
—
—
9.8e-01
1.3e+00
cases:11.19%
controls:5.88%
cases:6.62%
controls:2.82%
—
—
—
—
—
—
cases:4.48%
controls:1.73%
cases:20.51%
controls:6.63%
15
78
119
1249
9
38
127
1309
—
—
—
6
23
128
1308
24
78
93
1099
Neurology
13 [38004458]
6.7e-01
1.3e+00
-1.0e+50
—
—
9.2e-01
5.5e-01
cases:13.43%
controls:7.39%
cases:9.56%
controls:2.82%
cases:0.00%
controls:0.59%
—
—
—
—
cases:8.96%
controls:3.76%
cases:14.53%
controls:8.92%
18
98
116
1229
13
38
123
1309
0
8
136
1339
—
—
12
50
122
1281
17
105
100
1072
Short blood count panel - Blood
55429-5 [40758558]
—
1.3e+00
—
—
—
1.1e+00
9.1e-01
—
—
cases:8.82%
controls:2.67%
—
—
—
—
—
—
cases:6.72%
controls:2.33%
cases:11.97%
controls:5.18%
—
12
36
124
1311
—
—
—
9
31
125
1300
14
61
103
1116
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
1.4e-01
7.4e-01
—
—
—
8.4e-01
1.2e+00
cases:4.48%
controls:3.92%
cases:4.41%
controls:2.15%
—
—
—
—
—
—
cases:5.22%
controls:2.33%
cases:15.38%
controls:5.18%
6
52
128
1275
6
29
130
1318
—
—
—
7
31
127
1300
18
61
99
1116
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
4.3e-01
1.2e+00
-1.0e+50
—
—
6.9e-01
6.4e-01
cases:10.45%
controls:7.08%
cases:11.03%
controls:3.64%
cases:0.00%
controls:0.97%
—
—
—
—
cases:5.97%
controls:3.08%
cases:15.38%
controls:8.75%
14
94
120
1233
15
49
121
1298
0
13
136
1334
—
—
8
41
126
1290
18
103
99
1074
Other and unspecified abdominal pain
R10.4 [45568113]
6.4e-01
1.4e+00
—
—
—
1.3e+00
1.2e+00
cases:10.45%
controls:5.80%
cases:6.62%
controls:1.71%
—
—
—
—
—
—
cases:5.97%
controls:1.73%
cases:17.09%
controls:6.12%
14
77
120
1250
9
23
127
1324
—
—
—
8
23
126
1308
20
72
97
1105
Bacteria [Presence] in Urine
87829-8 [36304419]
1.4e-01
7.8e-01
—
—
—
7.1e-01
1.2e+00
cases:4.48%
controls:3.92%
cases:4.41%
controls:2.08%
—
—
—
—
—
—
cases:4.48%
controls:2.25%
cases:15.38%
controls:5.44%
6
52
128
1275
6
28
130
1319
—
—
—
6
30
128
1301
18
64
99
1113
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
4.6e-01
1.1e+00
-1.0e+50
—
-1.0e+50
4.8e-01
-3.1e-01
cases:17.16%
controls:11.53%
cases:10.29%
controls:3.64%
cases:0.00%
controls:0.37%
—
—
cases:0.00%
controls:0.67%
cases:5.22%
controls:3.31%
cases:10.26%
controls:13.42%
23
153
111
1174
14
49
122
1298
0
5
136
1342
—
0
9
136
1336
7
44
127
1287
12
158
105
1019
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
8.7e-02
—
—
—
—
1.1e+00
1.1e+00
cases:5.97%
controls:5.50%
—
—
—
—
—
—
—
—
cases:5.22%
controls:1.88%
cases:17.09%
controls:6.46%
8
73
126
1254
—
—
—
—
7
25
127
1306
20
76
97
1101
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
6.3e-01
8.3e-01
—
—
—
6.3e-01
1.1e+00
cases:6.72%
controls:3.69%
cases:5.15%
controls:2.30%
—
—
—
—
—
—
cases:3.73%
controls:2.03%
cases:11.97%
controls:4.42%
9
49
125
1278
7
31
129
1316
—
—
—
5
27
129
1304
14
52
103
1125
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
2.1e-01
6.6e-01
—
—
—
1.0e+00
7.1e-01
cases:16.42%
controls:13.72%
cases:12.50%
controls:6.90%
—
—
—
—
—
—
cases:15.67%
controls:6.39%
cases:29.06%
controls:16.74%
22
182
112
1145
17
93
119
1254
—
—
—
21
85
113
1246
34
197
83
980
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
4.5e-02
8.3e-01
—
—
—
5.0e-01
1.0e+00
cases:7.46%
controls:7.16%
cases:8.09%
controls:3.71%
—
—
—
—
—
—
cases:5.22%
controls:3.23%
cases:23.08%
controls:9.94%
10
95
124
1232
11
50
125
1297
—
—
—
7
43
127
1288
27
117
90
1060
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
3.2e-01
6.7e-01
—
—
—
9.5e-01
9.8e-01
cases:10.45%
controls:7.84%
cases:6.62%
controls:3.49%
—
—
—
—
—
—
cases:6.72%
controls:2.70%
cases:20.51%
controls:8.84%
14
104
120
1223
9
47
127
1300
—
—
—
9
36
125
1295
24
104
93
1073
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
1.4e-01
6.0e-01
—
—
—
9.8e-01
4.9e-01
cases:16.42%
controls:14.62%
cases:11.76%
controls:6.83%
—
—
—
—
—
—
cases:15.67%
controls:6.54%
cases:25.64%
controls:17.42%
22
194
112
1133
16
92
120
1255
—
—
—
21
87
113
1244
30
205
87
972
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
1.9e-01
8.3e-01
—
—
—
6.0e-01
9.7e-01
cases:5.22%
controls:4.37%
cases:5.15%
controls:2.30%
—
—
—
—
—
—
cases:5.22%
controls:2.93%
cases:15.38%
controls:6.46%
7
58
127
1269
7
31
129
1316
—
—
—
7
39
127
1292
18
76
99
1101
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
3.8e-01
8.4e-01
—
—
1.4e+00
9.4e-01
6.5e-01
cases:17.16%
controls:12.36%
cases:16.18%
controls:7.72%
—
—
—
—
cases:5.15%
controls:1.26%
cases:17.16%
controls:7.51%
cases:29.91%
controls:18.18%
23
164
111
1163
22
104
114
1243
—
—
7
17
129
1328
23
100
111
1231
35
214
82
963
Obstetrics / Gynecology
16 [38004461]
2.4e-01
7.0e-01
1.6e+00
—
1.5e+00
8.8e-01
6.9e-01
cases:21.64%
controls:17.78%
cases:15.44%
controls:8.31%
cases:5.88%
controls:1.26%
—
—
cases:5.15%
controls:1.19%
cases:17.16%
controls:7.89%
cases:30.77%
controls:18.18%
29
236
105
1091
21
112
115
1235
8
17
128
1330
—
7
16
129
1329
23
105
111
1226
36
214
81
963
Outpatient Hospital
22 [8756]
1.4e-01
6.0e-01
1.2e+00
—
1.4e+00
8.9e-01
7.5e-01
cases:25.37%
controls:22.76%
cases:12.50%
controls:7.28%
cases:3.68%
controls:1.11%
—
—
cases:3.68%
controls:0.89%
cases:13.43%
controls:6.01%
cases:30.77%
controls:17.42%
34
302
100
1025
17
98
119
1249
5
15
131
1332
—
5
12
131
1333
18
80
116
1251
36
205
81
972
flucloxacillin; oral, parenteral
J01CF05 [21602857]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
0
6
134
1321
—
—
—
—
0
5
134
1326
—
Overall medication plan or its review
SPAT1252 [2001700353]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
10
117
1167
Juvenile polyarthritis (seronegative)
M08.3 [45596450]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Contusion of other and unspecified parts of foot
S90.3 [45584475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
134
1318
—
—
—
—
—
—
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
-1.5e-01
5.0e-01
—
—
—
9.0e-02
-4.2e-02
cases:11.19%
controls:12.74%
cases:12.50%
controls:7.94%
—
—
—
—
—
—
cases:9.70%
controls:8.94%
cases:24.79%
controls:25.57%
15
169
119
1158
17
107
119
1240
—
—
—
13
119
121
1212
29
301
88
876
ramipril and diuretics
C09BA05 [21601807]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Bile acid [Moles/volume] in Serum --fasting
35562-8 [3034274]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
0
10
136
1337
—
—
—
0
11
134
1320
—
Custom moulded cast, unspecified region
TNX33 [2001308564]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
134
1321
—
—
—
—
—
—
phenoxymethylpenicillin; oral
J01CE02 [21602842]
-4.8e-01
-1.1e-01
—
—
-1.0e+50
—
-2.4e-01
cases:9.70%
controls:14.77%
cases:4.41%
controls:4.90%
—
—
—
—
cases:0.00%
controls:0.37%
—
—
cases:11.97%
controls:14.70%
13
196
121
1131
6
66
130
1281
—
—
0
5
136
1340
—
14
173
103
1004
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
0
8
136
1339
—
—
—
—
—
Intraoperative use of conventional X-ray imaging
ZXM10 [2001311446]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Recurrent depressive disorder, current episode moderate
F33.1 [45576543]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
6
134
1321
—
—
—
—
—
0
8
117
1169
Lumbar epidural anesthesia
WX306 [2001310796]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.06%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
0
14
134
1313
0
7
136
1340
—
—
—
—
—
Sprain and strain involving (anterior)(posterior) cruciate ligament of knee
S83.5 [45608523]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
lymecycline; oral, parenteral
J01AA04 [21602802]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
7
134
1324
—
Periodic health check-up of children and adolescents
SPAT1315 [2001700416]
-1.1e-01
—
—
—
—
—
2.9e-01
cases:4.48%
controls:4.97%
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:3.23%
6
66
128
1261
—
—
—
—
—
5
38
112
1139
Procedure duration 90 to 119 minutes
ZXE13 [2001311404]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
0
5
136
1342
—
—
—
—
0
5
117
1172
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
-1.5e-02
4.4e-01
1.2e+00
—
1.2e+00
1.4e-01
3.5e-02
cases:33.58%
controls:33.91%
cases:20.59%
controls:14.33%
cases:4.41%
controls:1.41%
—
—
cases:5.88%
controls:1.93%
cases:17.91%
controls:15.93%
cases:37.61%
controls:36.79%
45
450
89
877
28
193
108
1154
6
19
130
1328
—
8
26
128
1319
24
212
110
1119
44
433
73
744
Preventive oral health care
SCA02 [2001310303]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
0
10
136
1337
—
—
—
—
—
Telehealth
OMOP5556618 [722455]
3.5e-01
7.8e-01
—
—
9.8e-01
1.3e-01
2.7e-01
cases:29.10%
controls:22.38%
cases:16.91%
controls:8.54%
—
—
—
—
cases:3.68%
controls:1.41%
cases:8.96%
controls:7.96%
cases:25.64%
controls:20.82%
39
297
95
1030
23
115
113
1232
—
—
5
19
131
1326
12
106
122
1225
30
245
87
932
Tissue Pathology biopsy report
66121-5 [40768804]
4.0e-01
-1.0e+50
—
—
—
—
7.2e-01
cases:7.46%
controls:5.12%
cases:0.00%
controls:2.30%
—
—
—
—
—
—
—
—
cases:11.97%
controls:6.20%
10
68
124
1259
0
31
136
1316
—
—
—
—
14
73
103
1104
Retinal detachment with retinal break
H33.0 [45547857]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
6
117
1171
Special examination, unspecified
Z01.9 [45576123]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
8
117
1169
Car occupant [any] injured in unspecified traffic accident
V49.9 [45566025]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
misoprostol; oral
A02BB01 [21600093]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.68%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
0
9
134
1318
0
5
136
1342
—
—
—
—
—
Contusion of toe(s) without damage to nail
S90.1 [45550695]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Contusion of elbow
S50.0 [45597855]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
5
134
1322
—
—
—
—
—
0
8
117
1169
Other contraceptive management
Z30.8 [45571338]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
7
117
1170
Ankylosing spondylitis
M45 [45591841]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
0
7
134
1320
—
—
—
—
—
0
5
117
1172
Difficulties in perfomrming procedure
ZXD30 [2001311389]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
134
1321
—
—
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.1e+00
1.0e+00
—
—
—
8.3e-01
1.3e+00
cases:4.48%
controls:1.58%
cases:3.68%
controls:1.34%
—
—
—
—
—
—
cases:3.73%
controls:1.65%
cases:6.84%
controls:2.04%
6
21
128
1306
5
18
131
1329
—
—
—
5
22
129
1309
8
24
109
1153
Partial excision of intracranial lesion
AAB10 [2001300257]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Examination and observation for unspecified reason
Z04.9 [45605102]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
134
1320
—
—
—
—
—
—
Attendant Care Provider
3747A0650X [38004431]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
nifedipine; oral, parenteral
C08CA05 [21601751]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
134
1319
—
—
—
—
—
—
Acute nasopharyngitis [common cold]
J00 [45562431]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Glucose tolerance 2 hours gestational panel - Serum or Plasma
81324-6 [21492888]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
0
7
136
1340
—
—
—
—
0
10
117
1167
Supine thorax X-ray examination
GD1QA [2001303648]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
0
5
134
1326
—
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
—
—
—
—
—
5.8e-01
7.7e-01
—
—
—
—
—
—
—
—
—
—
cases:4.48%
controls:2.55%
cases:11.97%
controls:5.95%
—
—
—
—
—
6
34
128
1297
14
70
103
1107
Major dressing of wound of skin of lower limb
QDB10 [2001309970]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Synovitis and tenosynovitis, unspecified
M65.9 [45567618]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
6
117
1171
Extensive assessment of psychosocial situation
SPAT1241 [2001700342]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
General health counselling
SPAT1312 [2001700413]
1.9e-02
9.5e-01
—
—
—
8.2e-01
6.6e-01
cases:8.21%
controls:8.06%
cases:6.62%
controls:2.67%
—
—
—
—
—
—
cases:4.48%
controls:2.03%
cases:11.97%
controls:6.54%
11
107
123
1220
9
36
127
1311
—
—
—
6
27
128
1304
14
77
103
1100
Other angina pectoris unspecified coronary artery status
I20.89 [2000502401]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
General Practice
1 [38004446]
-3.4e-01
3.2e-02
—
—
—
—
4.4e-01
cases:8.21%
controls:11.15%
cases:3.68%
controls:3.56%
—
—
—
—
—
—
—
—
cases:17.09%
controls:11.72%
11
148
123
1179
5
48
131
1299
—
—
—
—
20
138
97
1039
Sinusitis acute/chronic
R75 [2002000943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
6
117
1171
Bacteria identified in Stool by Culture
625-4 [3025941]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
7
136
1340
—
—
—
—
—
disulfiram; oral
N07BB01 [21604821]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
134
1319
—
—
—
—
—
—
Contusion of other and unspecified parts of lower leg
S80.1 [45550389]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
6
117
1171
chondroitin sulfate
M01AX25 [21604013]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
0
6
134
1321
0
6
136
1341
—
—
—
0
8
134
1323
—
Public health laboratory ask at order entry panel
81959-9 [21494755]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
7
134
1324
—
Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay
29662-4 [3012220]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
0
9
134
1318
—
—
—
—
—
0
5
117
1172
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
—
—
—
—
—
-1.0e+50
9.6e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:6.84%
controls:2.72%
—
—
—
—
—
0
10
134
1321
8
32
109
1145
doxylamine, combinations
R06AA59 [40254475]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
134
1321
—
—
—
—
—
—
Nausea and vomiting
R11 [45539317]
-1.0e+50
—
—
—
—
—
1.2e+00
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:1.27%
0
16
134
1311
—
—
—
—
—
5
15
112
1162
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
0
5
136
1340
—
—
Cystitis
N30 [45563012]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
0
15
117
1162
dapagliflozin; oral
A10BK01 [1123890]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
dexamethasone; local oral
A01AC02 [21600035]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
0
11
134
1316
—
—
—
—
—
0
6
117
1171
Salmonella sp identified in Stool by Organism specific culture
20955-1 [3004716]
1.0e+00
—
—
—
—
—
—
cases:3.73%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
129
1309
—
—
—
—
—
—
Gastroenteritis presumed infection
D73 [2002000371]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
134
1320
—
—
—
—
—
—
perphenazine; oral, parenteral, rectal
N05AB03 [21604502]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
134
1319
—
—
—
—
—
—
Paracervical blockade
WX234 [2001310789]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
0
11
134
1316
—
—
—
—
—
0
5
117
1172
Insect bite/sting
S12 [2002000977]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
134
1321
—
—
—
—
—
—
Oxygen capacity [Volume Fraction] in Arterial blood
59275-8 [40762366]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.38%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
0
5
136
1342
—
—
—
—
—
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
—
—
—
0
9
136
1338
—
—
—
—
—
Neoplasm of uncertain or unknown behaviour: Skin
D48.5 [45586113]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Obesity, unspecified
E66.9 [45576460]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.38%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
0
6
136
1341
—
—
—
—
—
Outcome of delivery
Z37 [45581024]
7.5e-02
—
—
—
—
1.1e+00
5.1e-01
cases:8.96%
controls:8.36%
—
—
—
—
—
—
—
—
cases:8.21%
controls:2.85%
cases:11.97%
controls:7.56%
12
111
122
1216
—
—
—
—
11
38
123
1293
14
89
103
1088
covid-19, RNA-based vaccine
J07BN01 [954934]
-1.0e-01
-3.6e-01
—
—
-1.0e+50
—
-1.6e-01
cases:7.46%
controls:8.21%
cases:5.15%
controls:7.20%
—
—
—
—
cases:0.00%
controls:0.37%
—
—
cases:17.95%
controls:20.48%
10
109
124
1218
7
97
129
1250
—
—
0
5
136
1340
—
21
241
96
936
codeine and paracetamol
N02AJ06 [1123647]
2.1e-01
—
—
—
—
1.7e-01
-1.3e-03
cases:11.19%
controls:9.27%
—
—
—
—
—
—
—
—
cases:3.73%
controls:3.16%
cases:11.97%
controls:11.98%
15
123
119
1204
—
—
—
—
5
42
129
1289
14
141
103
1036
Hip symptom/complaint
L13 [2002000637]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
6
136
1341
—
—
—
—
—
Nonorganic sleep disorders
F51 [45552491]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Plain photography of ocular fundus
CK2S4 [2001301455]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
amoxicillin; oral, parenteral
J01CA04 [21602823]
-3.6e-01
5.6e-01
-1.0e+50
—
—
1.3e-02
3.7e-01
cases:17.16%
controls:22.83%
cases:10.29%
controls:6.16%
cases:0.00%
controls:0.89%
—
—
—
—
cases:8.21%
controls:8.11%
cases:27.35%
controls:20.56%
23
303
111
1024
14
83
122
1264
0
12
136
1335
—
—
11
108
123
1223
32
242
85
935
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
—
—
-1.0e+50
—
-1.0e+50
—
1.3e+00
—
—
—
—
cases:0.00%
controls:0.37%
—
—
cases:0.00%
controls:0.37%
—
—
cases:5.98%
controls:1.70%
—
—
0
5
136
1342
—
0
5
136
1340
—
7
20
110
1157
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
—
-1.0e+50
—
—
—
—
1.3e+00
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:9.40%
controls:2.80%
—
0
9
136
1338
—
—
—
—
11
33
106
1144
Cardiology
6 [38004451]
1.5e-01
—
—
—
—
—
7.1e-01
cases:3.73%
controls:3.24%
—
—
—
—
—
—
—
—
—
—
cases:9.40%
controls:4.84%
5
43
129
1284
—
—
—
—
—
11
57
106
1120
Spacing, abnormal of tooth or teeth
K07.30 [2000502776]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
5
134
1322
—
—
—
—
—
0
7
117
1170
Trisomy 21 risk [Likelihood] in Fetus
43995-0 [3043238]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:1.78%
—
—
—
—
—
—
6
21
111
1156
Positioning and fixed attachment of single bracket (Bracket with fixed attachment)
SJC01 [2001310428]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
134
1318
—
—
—
—
—
—
Bacteria identified in Blood by Culture
600-7 [3023368]
—
—
—
—
—
—
7.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.40%
controls:4.67%
—
—
—
—
—
—
11
55
106
1122
ispaghula (psylla seeds); oral
A06AC01 [21600555]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
11
136
1336
—
—
—
—
—
dexbrompheniramine, combinations
R06AB56 [21603469]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.90%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.78%
0
12
134
1315
0
6
136
1341
—
—
—
—
0
21
117
1156
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
—
—
—
—
—
—
—
—
—
—
—
0
10
136
1337
—
—
—
—
—
Physical abuse
T74.1 [45594864]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
134
1321
—
—
—
—
—
—
Other leisure activity accident
Y94.8 [2000503731]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Sciatica
M54.3 [45586994]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
134
1320
—
—
—
—
—
—
Influenza virus B Ag [Presence] in Specimen
31864-2 [3003740]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
134
1321
—
—
—
—
—
—
hepatitis A, inactivated, whole virus
J07BC02 [21601339]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
6
117
1171
azelastine; nasal
R01AC03 [21605035]
—
—
—
—
—
—
3.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.84%
controls:4.76%
—
—
—
—
—
—
8
56
109
1121
Acute upper respiratory infection, unspecified
J06.9 [45562437]
-1.3e-01
2.0e-02
-1.0e+50
—
—
2.3e-02
3.8e-01
cases:8.21%
controls:9.27%
cases:5.15%
controls:5.05%
cases:0.00%
controls:0.52%
—
—
—
—
cases:5.22%
controls:5.11%
cases:22.22%
controls:16.31%
11
123
123
1204
7
68
129
1279
0
7
136
1340
—
—
7
68
127
1263
26
192
91
985
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
2.5e-02
4.2e-01
—
—
—
-2.2e-01
-1.8e-01
cases:17.16%
controls:16.80%
cases:14.71%
controls:10.17%
—
—
—
—
—
—
cases:8.96%
controls:10.89%
cases:27.35%
controls:31.01%
23
223
111
1104
20
137
116
1210
—
—
—
12
145
122
1186
32
365
85
812
Emergency procedure
ZXD00 [2001311385]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
134
1321
—
—
—
—
—
—
fluticasone, combinations
R01AD58 [43534837]
—
—
—
—
—
—
3.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.84%
controls:4.76%
—
—
—
—
—
—
8
56
109
1121
fusidic acid; ointment
D06AX01 [21602062]
1.7e-01
—
—
—
—
—
2.1e-01
cases:5.22%
controls:4.45%
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:3.48%
7
59
127
1268
—
—
—
—
—
5
41
112
1136
Extraction of root of tooth
EBA30 [2001301929]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
6
117
1171
Kappa light chains.free [Mass/volume] in Serum
36916-5 [3034860]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Oncology Clinic/Center
261QX0200X [38004268]
5.5e-01
—
—
—
—
—
2.6e-01
cases:4.48%
controls:2.64%
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:3.31%
6
35
128
1292
—
—
—
—
—
5
39
112
1138
Maternal care for excessive fetal growth
O36.6 [45543983]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
134
1319
—
—
—
—
—
—
Low back symptom/complaint
L03 [2002000628]
6.8e-01
—
—
—
—
7.9e-01
9.4e-01
cases:5.22%
controls:2.71%
—
—
—
—
—
—
—
—
cases:3.73%
controls:1.73%
cases:9.40%
controls:3.91%
7
36
127
1291
—
—
—
—
5
23
129
1308
11
46
106
1131
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
—
—
—
—
—
—
9.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.98%
controls:2.38%
—
—
—
—
—
—
7
28
110
1149
Acceptance of acknowledgement of paternity of child born outside of marriage before the birth of the child at the maternity clinic. Paternity Act, Section 16.
SPAT1399 [2001700499]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.21%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.10%
0
16
134
1311
—
—
—
—
—
0
13
117
1164
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
0
6
136
1341
—
—
—
0
5
134
1326
—
hydroxocobalamin; parenteral
B03BA03 [21601123]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
0
10
117
1167
Hand/finger symptom/complaint
L12 [2002000636]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.98%
controls:2.04%
—
—
—
—
—
—
7
24
110
1153
Insulin-like growth factor-I [Moles/volume] in Serum or Plasma
29775-4 [3014326]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
COVID-19, virus not identified
U07.2 [45756094]
—
—
—
—
—
—
2.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.84%
controls:5.18%
—
—
—
—
—
—
8
61
109
1116
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
5.1e-01
—
—
—
—
—
—
cases:6.72%
controls:4.14%
—
—
—
—
—
—
—
—
—
—
—
—
9
55
125
1272
—
—
—
—
—
—
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
313 [2001600274]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
134
1320
—
—
—
—
—
—
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
—
—
—
—
—
—
7.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.84%
controls:3.31%
—
—
—
—
—
—
8
39
109
1138
Rheumatoid arthritis, unspecified
M06.9 [45533705]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Diverticular disease of large intestine without perforation or abscess
K57.3 [45567316]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
12
117
1165
Health check-up performed during second study year in students of upper secondary schools, vocational schools etc.
SPAT1364 [2001700465]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
0
9
136
1338
—
—
—
—
0
8
117
1169
Transient cerebral ischaemic attack, unspecified
G45.9 [45542892]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
0
5
134
1322
—
—
—
—
—
0
5
117
1172
etonogestrel; implant
G03AC08 [21602504]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
nafarelin; nasal
H01CA02 [21602712]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
2.9e-01
1.1e+00
-1.0e+50
—
—
1.2e+00
3.8e-01
cases:4.48%
controls:3.39%
cases:4.41%
controls:1.56%
cases:0.00%
controls:0.45%
—
—
—
—
cases:4.48%
controls:1.43%
cases:8.55%
controls:6.03%
6
45
128
1282
6
21
130
1326
0
6
136
1341
—
—
6
19
128
1312
10
71
107
1106
Separate planning of oral and dental treatment, standard
SAC01 [2001310283]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
topiramate; oral
N03AX11 [21604433]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
8
134
1319
0
6
136
1341
—
—
—
—
—
ibuprofen
R02AX02 [1588667]
-1.5e-02
4.4e-01
1.2e+00
—
1.2e+00
1.4e-01
3.5e-02
cases:33.58%
controls:33.91%
cases:20.59%
controls:14.33%
cases:4.41%
controls:1.41%
—
—
cases:5.88%
controls:1.93%
cases:17.91%
controls:15.93%
cases:37.61%
controls:36.79%
45
450
89
877
28
193
108
1154
6
19
130
1328
—
8
26
128
1319
24
212
110
1119
44
433
73
744
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
-6.4e-02
5.3e-01
—
—
—
-2.1e-01
-2.7e-01
cases:14.93%
controls:15.75%
cases:13.24%
controls:8.24%
—
—
—
—
—
—
cases:6.72%
controls:8.19%
cases:21.37%
controls:26.17%
20
209
114
1118
18
111
118
1236
—
—
—
9
109
125
1222
25
308
92
869
mercaptopurine
L01BB02 [21601428]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Other oral or dental procedure
SXC05 [2001310586]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
7
136
1340
—
—
—
—
—
Guidance related to psychoactive substances / risk behaviour
SPAT1309 [2001700410]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
fluticasone furoate
R03BA09 [45893496]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
136
1342
—
0
5
136
1340
—
—
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
0
5
136
1342
—
—
—
—
Biopsy of endometrium
LCA06 [2001306551]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.85%
—
—
—
—
—
—
5
10
112
1167
Dizziness and giddiness
R42 [45568132]
4.5e-01
—
—
—
—
—
7.0e-01
cases:3.73%
controls:2.41%
—
—
—
—
—
—
—
—
—
—
cases:5.98%
controls:3.06%
5
32
129
1295
—
—
—
—
—
7
36
110
1141
Alpha tocopherol [Moles/volume] in Serum or Plasma
14590-4 [3000208]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
6
117
1171
Campylobacter sp identified in Tissue by Organism specific culture
20740-7 [3006418]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
7
117
1170
combinations of corticosteroids
D07XB30 [21602188]
7.2e-02
—
—
—
—
—
2.4e-01
cases:10.45%
controls:9.80%
—
—
—
—
—
—
—
—
—
—
cases:11.11%
controls:8.92%
14
130
120
1197
—
—
—
—
—
13
105
104
1072
Deviated nasal septum
J34.2 [45562448]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
9
134
1318
—
—
—
—
—
0
8
117
1169
levonorgestrel
G03AC03 [21602499]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
6
136
1341
—
—
—
—
—
tetanus toxoid, combinations with diphtheria toxoid
J07AM51 [21601317]
8.9e-01
-1.0e+50
—
—
—
—
—
cases:4.48%
controls:1.88%
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
6
25
128
1302
0
8
136
1339
—
—
—
—
—
quetiapine; oral
N05AH04 [21604544]
—
4.8e-01
—
—
—
3.9e-01
6.8e-01
—
—
cases:3.68%
controls:2.30%
—
—
—
—
—
—
cases:3.73%
controls:2.55%
cases:6.84%
controls:3.57%
—
5
31
131
1316
—
—
—
5
34
129
1297
8
42
109
1135
Caries of dentine
K02.1 [45548134]
1.2e-01
-3.7e-01
—
—
—
-6.6e-02
1.4e-01
cases:16.42%
controls:14.85%
cases:4.41%
controls:6.24%
—
—
—
—
—
—
cases:5.22%
controls:5.56%
cases:19.66%
controls:17.59%
22
197
112
1130
6
84
130
1263
—
—
—
7
74
127
1257
23
207
94
970
clidinium and psycholeptics
A03CA02 [21600204]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
6
136
1341
—
—
—
—
—
Periodontal treatment, very brief
SDA01 [2001310326]
-2.0e-01
—
—
—
—
—
5.7e-01
cases:3.73%
controls:4.52%
—
—
—
—
—
—
—
—
—
—
cases:8.55%
controls:5.01%
5
60
129
1267
—
—
—
—
—
10
59
107
1118
pH of Urine
2756-5 [3015736]
-4.3e-01
-1.0e-02
—
—
-1.0e+50
7.2e-01
1.4e-01
cases:4.48%
controls:6.71%
cases:3.68%
controls:3.71%
—
—
—
—
cases:0.00%
controls:0.67%
cases:5.97%
controls:3.01%
cases:12.82%
controls:11.30%
6
89
128
1238
5
50
131
1297
—
—
0
9
136
1336
8
40
126
1291
15
133
102
1044
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
0
8
136
1339
—
—
—
0
5
134
1326
—
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
—
—
—
—
—
—
2.7e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:4.16%
—
—
—
—
—
—
5
49
112
1128
pH of Arterial blood
2744-1 [3019977]
—
-1.0e+50
—
—
—
—
1.5e+00
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:5.13%
controls:1.19%
—
0
6
136
1341
—
—
—
—
6
14
111
1163
Anomalies of dental arch relationship
K07.25 [2000502771]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Other seropositive rheumatoid arthritis
M05.8 [45538634]
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
5
136
1340
0
6
134
1325
—
Fever
A03 [2002000144]
3.9e-01
—
—
—
—
—
7.3e-01
cases:4.48%
controls:3.09%
—
—
—
—
—
—
—
—
—
—
cases:5.13%
controls:2.55%
6
41
128
1286
—
—
—
—
—
6
30
111
1147
Preventive oral health care, extensive
SCA03 [2001310304]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
—
—
—
—
—
—
0
9
117
1168
Open wound of scalp
S01.0 [45592468]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.76%
0
5
134
1322
—
—
—
—
—
0
9
117
1168
bisoprolol; oral
C07AB07 [21601689]
-1.8e-01
1.2e-01
-1.0e+50
—
—
-1.1e-01
4.7e-01
cases:5.22%
controls:6.18%
cases:5.15%
controls:4.60%
cases:0.00%
controls:1.34%
—
—
—
—
cases:4.48%
controls:4.96%
cases:13.68%
controls:9.01%
7
82
127
1245
7
62
129
1285
0
18
136
1329
—
—
6
66
128
1265
16
106
101
1071
Noninvasive ventilation
WX725 [2001310828]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
8
117
1169
Bicarbonate [Moles/volume] in Serum or Plasma
1963-8 [3016293]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
6
136
1341
—
—
—
—
Glomerular filtration rate (GFR) Isotope mesurement
KA1MN [2001305637]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Teething syndrome
K00.7 [45552905]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.38%
cases:0.00%
controls:0.76%
—
—
—
—
—
0
5
134
1326
0
9
117
1168
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
9.2e-02
4.2e-01
—
—
—
-2.8e-01
-1.6e-01
cases:17.16%
controls:15.90%
cases:13.97%
controls:9.65%
—
—
—
—
—
—
cases:7.46%
controls:9.62%
cases:26.50%
controls:29.74%
23
211
111
1116
19
130
117
1217
—
—
—
10
128
124
1203
31
350
86
827
Adenotomy
EMB30 [2001302268]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
7
136
1340
—
—
—
—
—
Fetal Nuchal fold Thickness US
12146-7 [3005033]
—
—
—
—
—
-1.0e+50
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:5.13%
controls:1.70%
—
—
—
—
—
0
6
134
1325
6
20
111
1157
Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder
S46.0 [45544769]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172
Chronic arrhythmias
207 [2001600205]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Stomatognathic treatment, demanding
SHA03 [2001310407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
134
1319
—
—
—
—
—
—
Pain in joint
M25.5 [45586941]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.11%
controls:4.16%
—
—
—
—
—
—
13
49
104
1128
Progesterone [Moles/volume] in Serum or Plasma
14890-8 [3005082]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Valproate [Moles/volume] in Serum or Plasma
14946-8 [3009466]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
0
6
117
1171
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
-1.0e+50
-1.0e+50
—
—
—
—
1.1e+00
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:4.27%
controls:1.53%
0
10
134
1317
0
9
136
1338
—
—
—
—
5
18
112
1159
Medicine administration
WVA20 [2001310740]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Postpartum check-up
SPAT1380 [2001700480]
—
—
—
—
—
—
4.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:2.89%
—
—
—
—
—
—
5
34
112
1143
Lower urinary tract urodynamic studies
252896003 [4099392]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
134
1321
—
—
—
—
—
—
Intravenous general anesthesia
WX404 [2001310807]
—
—
-1.0e+50
—
—
—
1.1e+00
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:5.13%
controls:1.78%
—
—
0
5
136
1342
—
—
—
6
21
111
1156
Gestational [pregnancy-induced] hypertension
O13 [45539091]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
6
134
1321
0
5
136
1342
—
—
—
—
0
8
117
1169
pH of Urine by Test strip
5803-2 [3022621]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
0
7
134
1320
0
7
136
1340
—
—
—
—
—
Alpha thalassaemia
D56.0 [45542706]
—
—
—
1.0e+50
—
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:25.74%
controls:0.00%
—
—
cases:8.96%
controls:0.00%
cases:8.55%
controls:0.00%
—
—
—
35
0
101
1347
—
12
0
122
1331
10
0
107
1177
Cardiac arrhythmia, unspecified
I49.9 [45581778]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
7
136
1340
—
—
—
—
—
Contraceptive management
Z30 [45756073]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
134
1321
—
—
—
—
—
—
ciclesonide; nasal
R01AD13 [43534836]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
0
11
134
1316
—
—
—
—
0
6
134
1325
—
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
—
-1.0e+50
—
—
—
—
1.6e+00
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:5.13%
controls:1.10%
—
0
6
136
1341
—
—
—
—
6
13
111
1164
Dislocation of patella
S83.0 [45598912]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
134
1321
—
—
—
—
—
—
Hospital outpatient
ZY010 [2001311599]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.04%
cases:0.00%
controls:0.45%
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.68%
cases:0.00%
controls:1.36%
—
0
14
136
1333
0
6
136
1341
—
0
8
136
1337
0
9
134
1322
0
16
117
1161
Issue of repeat prescription
Z76.0 [45542456]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
0
11
136
1336
0
5
136
1342
—
—
—
—
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
134
1320
—
—
—
—
—
—
piroxicam; ointment
M02AA07 [21604043]
7.0e-01
—
—
—
—
—
—
cases:6.72%
controls:3.47%
—
—
—
—
—
—
—
—
—
—
—
—
9
46
125
1281
—
—
—
—
—
—
triamcinolone; nasal
R01AD11 [21605052]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
134
1320
—
—
—
—
—
—
Psychiatry
26 [38004469]
-3.7e-01
—
—
—
—
1.5e-01
-1.8e-01
cases:5.22%
controls:7.39%
—
—
—
—
—
—
—
—
cases:5.22%
controls:4.51%
cases:6.84%
controls:8.07%
7
98
127
1229
—
—
—
—
7
60
127
1271
8
95
109
1082
Acute stress reaction mild
F43.00 [2000501998]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
134
1322
—
—
—
—
—
—
Placement of orthodontic arch wire
SJD10 [2001310438]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
134
1319
—
—
—
—
—
—
Impacted cerumen
H61.2 [45562307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
134
1320
—
—
—
—
—
—
buspirone; oral
N05BE01 [21604601]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
134
1320
—
—
—
—
—
—
Contact with and exposure to unspecified communicable disease
Z20.9 [45595489]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
0
5
134
1322
—
—
—
—
—
0
7
117
1170
tacrolimus
D11AH01 [21602338]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.13%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
0
15
134
1312
0
5
136
1342
—
—
—
—
—
pivmecillinam; oral
J01CA08 [21602827]
-4.8e-01
—
-1.0e+50
—
-1.0e+50
—
-3.4e-01
cases:5.97%
controls:9.27%
—
—
cases:0.00%
controls:0.37%
—
—
cases:0.00%
controls:1.04%
—
—
cases:6.84%
controls:9.35%
8
123
126
1204
—
0
5
136
1342
—
0
14
136
1331
—
8
110
109
1067
Puncture of vitreous body with injection of medication
CKD05 [2001301407]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
5
117
1172

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
60
120
7.82
31.79
12.1
3.6
1.67
1.72
%
0.15
53
110
61
180
5.12
20.20
2.8
2.5
2.31
2.35
g/l
0.23
56
168
64
199
4.97
19.82
2.8
2.5
15.07
13.89
umol/l
0.41
57
189
82
326
4.49
18.12
3.1
2.1
3.47
2.65
mg/l
2.09
71
283
39
92
5.43
16.48
12.3
3.3
86.20
70.04
e9/l
1.45
29
65
70
305
3.50
12.45
9.2
5.2
84.64
91.51
%
1.42
70
300
113
673
4.08
12.06
9.6
3.1
115.94
85.37
ug/l
1.28
108
637
84
420
3.38
11.78
15.4
7.3
—
—
—
0
0
23
51
5.17
10.19
1.8
1.7
57.57
9.73
u/ml
—
8
10
28
74
4.45
10.06
1.9
1.2
—
—
—
0
0
16
14
12.68
9.33
1.6
1.3
—
—
—
0
0
83
466
2.83
8.64
2.2
1.9
102.33
96.11
pmol/l
0.68
51
240
41
157
3.25
8.55
1.9
1.6
1023.93
1162.98
nmol/l
0.36
28
123
97
604
2.83
8.05
11.8
7.1
15.12
12.28
umol/l
0.76
92
581
100
659
2.67
6.98
14.9
7.2
0.04
0.04
e9/l
0.10
85
562
100
661
2.65
6.91
14.9
7.1
0.55
0.56
e9/l
0.17
85
565
107
735
2.74
6.76
18.8
10.2
4.05
4.16
e9/l
0.16
87
644
101
677
2.62
6.67
16.5
7.7
0.15
0.19
e9/l
1.67
88
598
101
682
2.58
6.49
14.8
7.1
2.01
2.02
e9/l
0.05
89
605
16
28
6.28
6.36
1.1
1.0
—
—
—
0
0
76
468
2.31
5.77
6.0
4.5
17.55
40.24
e6/l
1.06
44
317
26
96
3.08
5.63
20.0
12.5
25.45
24.97
mmol/l
0.26
26
96
59
330
2.33
5.57
4.6
3.5
—
—
estimate
—
0
0
77
482
2.27
5.56
12.8
8.9
1.21
1.22
mmol/l
0.28
72
455
48
246
2.42
5.51
2.1
1.5
—
—
—
0
0
59
334
2.29
5.38
4.7
3.5
0.38
0.39
e6/l
0.02
37
249
39
184
2.53
5.33
4.3
3.7
1.71
2.97
e6/l
0.75
14
95
89
602
2.24
5.20
20.0
11.2
0.07
0.00
e9/l
0.53
70
479
67
406
2.21
5.13
8.0
2.4
—
—
—
0
0
81
533
2.18
5.00
13.9
8.9
1.21
1.21
mmol/l
0.06
71
466
14
30
5.05
4.83
1.1
1.0
—
—
—
0
0
54
306
2.22
4.82
1.5
1.6
20.90
21.24
nmol/l
0.06
47
270
63
391
2.08
4.38
4.6
3.6
15.83
40.20
e6/l
0.91
41
304
32
154
2.38
4.12
1.9
1.5
—
—
—
0
0
47
267
2.12
4.08
6.0
2.4
1.16
1.16
mg/l
0.00
32
201
50
291
2.10
4.07
5.7
4.5
—
—
—
0
0
70
465
1.98
3.93
2.5
2.2
—
—
—
0
0
24
104
2.57
3.85
20.6
13.3
—
—
—
0
0
69
459
1.96
3.83
9.4
6.1
36.64
36.37
g/l
0.13
64
442
61
390
1.97
3.79
16.4
6.1
—
—
—
0
0
59
379
1.94
3.57
2.4
1.8
—
—
—
0
0
11
27
4.32
3.47
7.1
6.3
70.46
63.46
%
0.36
11
27
28
138
2.28
3.40
11.2
9.7
105.29
104.51
mmol/l
0.44
28
138
82
595
1.87
3.36
7.6
3.0
—
—
estimate
—
0
0
10
24
4.39
3.26
1.2
1.1
—
—
—
0
0
89
668
1.86
3.22
8.8
6.2
6.45
6.29
mmol/l
0.35
80
610
52
330
1.90
3.21
6.6
3.9
7.41
7.40
ph
0.79
37
237
19
81
2.55
3.14
1.4
1.9
—
—
—
0
0
40
234
1.98
3.12
3.6
2.8
612.26
538.84
mosm/kgh2o
1.17
35
207
67
466
1.81
3.06
1.9
1.7
—
—
—
0
0
7
12
6.07
3.06
1.1
1.0
—
—
—
0
0
23
111
2.27
2.92
9.7
14.0
7.42
7.42
ph
0.16
13
60
6
9
6.89
2.89
1.3
2.1
—
—
—
0
0
6
9
6.89
2.89
1.2
1.0
—
—
—
0
0
12
39
3.26
2.85
1.3
1.7
144.00
136.37
au/ml
—
5
14
8
18
4.64
2.84
3.4
1.7
—
—
—
0
0
8
18
4.64
2.84
3.4
1.7
—
—
—
0
0
8
18
4.64
2.84
3.4
1.7
—
—
—
0
0
8
18
4.64
2.84
3.4
1.7
—
—
—
0
0
137
1236
2.96
2.83
23.6
14.1
22.73
22.21
mg/l
0.06
117
980
5
6
8.57
2.77
3.2
1.5
1.80
0.83
index
—
5
6
19
87
2.36
2.71
1.7
1.6
—
—
—
0
0
7
15
4.84
2.63
9.6
7.1
12.30
11.91
%
—
7
15
18
84
2.30
2.47
1.7
1.5
—
—
—
0
0
40
259
1.75
2.22
3.5
3.2
352.61
335.01
umol/l
0.47
33
238
11
42
2.75
2.20
1.4
1.4
—
98.57
—
0
7
114
979
1.77
2.10
5.5
4.3
14.50
14.64
pmol/l
0.21
108
906
12
50
2.53
2.08
7.7
5.0
1.20
1.53
%
0.47
12
50
23
128
1.95
2.04
1.3
1.2
—
—
—
0
0
50
352
1.64
2.03
2.1
1.5
2.24
2.16
g/l
0.12
25
216
12
51
2.48
2.01
7.7
4.9
0.63
0.62
%
0.01
12
51
23
130
1.91
1.96
2.2
1.6
—
—
—
0
0
5
11
4.66
1.95
12.0
4.1
27.34
36.97
%
—
5
11
16
80
2.12
1.88
23.8
8.7
24.56
24.27
mmol/l
0.18
16
80
6
17
3.63
1.85
2.5
1.9
—
—
—
0
0
9
35
2.67
1.83
1.2
1.3
—
—
—
0
0
12
54
2.33
1.79
3.7
14.0
—
—
—
0
0
54
398
1.57
1.78
4.6
3.1
—
0.29
—
0
7
18
97
1.98
1.75
1.9
2.0
—
—
—
0
0
41
284
1.62
1.75
5.6
4.0
18.51
14.04
mg/mmol
0.15
28
187
40
280
1.59
1.63
4.6
3.4
120.91
96.95
mg/l
0.13
29
187
5
14
3.66
1.63
1.0
1.3
—
—
—
0
0
6
20
3.08
1.60
1.3
1.2
—
—
—
0
0
70
557
1.50
1.59
4.5
3.4
6.33
6.26
ph
0.21
30
303
5
15
3.41
1.53
1.0
1.3
—
—
—
0
0
126
1146
1.76
1.49
6.5
5.1
1.86
1.82
mu/l
0.13
121
1081
6
22
2.80
1.45
2.5
2.7
17.67
15.78
%
—
6
22
13
67
2.03
1.43
4.5
7.4
—
—
—
0
0
26
170
1.65
1.38
1.9
2.2
—
—
—
0
0
14
76
1.93
1.35
1.5
1.2
—
—
—
0
0
15
85
1.85
1.28
1.4
1.4
219.28
273.90
miu/ml
—
9
44
82
692
1.43
1.28
4.7
4.0
0.00
0.00
estimate
-0.00
13
149
20
125
1.70
1.26
2.7
1.4
—
—
—
0
0
81
685
1.41
1.23
4.6
3.9
0.00
0.00
estimate
-0.00
15
153
34
244
1.51
1.23
1.7
1.3
15.11
29.74
iu/ml
—
9
67
5
19
2.69
1.22
1.2
1.2
—
—
—
0
0
6
26
2.36
1.20
1.5
1.4
—
—
—
0
0
80
678
1.40
1.19
4.7
3.9
0.00
0.00
estimate
-0.00
15
156
57
457
1.41
1.16
22.8
9.8
1.32
1.15
inr
1.31
48
382
13
73
1.86
1.15
1.3
1.2
—
—
—
0
0
54
431
1.40
1.13
2.0
1.8
—
—
—
0
0
5
21
2.43
1.10
2.8
2.1
1.90
1.88
mmol/l
—
5
21
119
1091
1.51
1.08
4.3
4.0
5.84
5.68
mmol/l
0.42
113
1009
40
307
1.42
1.03
3.8
3.4
—
—
—
0
0
5
23
2.21
0.99
5.8
3.5
4.78
4.99
kpa
—
5
23
5
23
2.21
0.99
5.8
3.5
8.84
8.46
kpa
—
5
23
42
329
1.39
0.96
1.8
1.9
—
—
—
0
0
45
358
1.37
0.94
3.6
2.8
—
—
—
0
0
18
119
1.59
0.93
1.1
1.4
—
—
—
0
0
6
29
2.11
0.90
1.0
1.2
—
—
—
0
0
12
72
1.73
0.88
1.8
1.4
—
—
—
0
0
42
510
0.75
0.80
2.8
2.6
—
—
—
0
0
6
34
1.80
0.77
5.0
3.8
7.43
7.41
ph
—
6
34
5
24
2.12
0.75
1.2
2.0
—
—
—
0
0
45
372
1.30
0.72
4.5
3.5
38.58
36.09
ng/l
0.05
32
217
106
1133
0.76
0.70
4.3
4.1
1.35
1.43
mmol/l
1.22
99
1071
5
27
1.88
0.69
1.6
1.2
1.60
4.92
u/ml
—
5
12
5
29
1.75
0.64
1.4
3.1
—
—
—
0
0
28
221
1.33
0.61
1.5
1.3
2.30
5.10
u/ml
1.09
11
89
46
391
1.26
0.59
1.6
1.4
0.43
1.59
u/ml
—
6
97
19
144
1.37
0.54
1.4
1.2
—
—
—
0
0
20
153
1.36
0.54
2.1
1.6
—
—
—
0
0
26
208
1.30
0.53
4.0
3.3
43.51
425.74
ng/l
1.30
16
133
12
84
1.47
0.51
3.0
1.4
11.18
16.33
iu/l
0.34
12
72
39
331
1.24
0.50
3.3
5.3
—
—
—
0
0
109
1147
0.80
0.50
4.8
4.5
2.62
2.73
mmol/l
0.72
102
1083
14
102
1.41
0.49
2.1
5.3
0.80
0.65
%
—
5
31
14
102
1.41
0.49
3.1
1.3
126.94
374.43
u/ml
0.55
14
96
7
47
1.51
0.48
2.1
1.9
—
—
—
0
0
108
1136
0.81
0.48
4.3
4.2
4.40
4.59
mmol/l
1.26
102
1076
98
1039
0.82
0.46
6.5
5.0
38.39
37.54
mmol/mol
0.32
91
986
7
50
1.42
0.45
1.4
1.2
—
—
—
0
0
116
1105
1.25
0.45
36.7
17.5
319.98
333.71
g/l
18.06
116
1100
100
1057
0.83
0.44
3.9
3.6
1.23
1.23
mmol/l
0.02
92
991
24
195
1.28
0.44
2.3
1.7
407.31
66857580.36
pmol/l
0.50
16
175
133
1289
1.38
0.44
18.6
11.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
5
36
1.40
0.38
3.8
17.2
0.82
0.86
%
—
5
31
6
42
1.45
0.36
1.7
1.1
—
—
—
0
0
23
269
0.83
0.31
1.3
1.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
17.7
—
710.33
—
0
12
0
12
0.00
0.21
0.0
27.3
—
1261.17
—
0
12
0
13
0.00
0.21
0.0
1.0
—
129.39
—
0
13
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
2.3
—
2.23
—
0
14
47
500
0.91
0.17
4.1
3.6
0.00
0.01
estimate
0.50
13
132
37
396
0.91
0.15
3.7
3.2
0.00
0.00
estimate
-0.00
12
128
16
148
1.09
0.06
1.1
1.2
—
—
—
0
0
11
120
0.91
0.05
3.9
3.9
—
—
—
0
0
35
360
0.96
0.03
3.7
3.9
0.00
0.01
estimate
0.50
14
146
12
121
0.99
0.00
2.0
1.5
—
—
—
0
0
21
206
1.02
0.00
2.0
2.2
55.73
108.44
ug/g
1.27
15
157
12
123
0.97
0.00
2.0
1.5
—
—
—
0
0
28
285
0.98
0.00
3.4
3.6
1.02
1.02
kg/l
0.46
12
192
12
122
0.98
0.00
2.1
1.5
—
—
—
0
0
11
112
0.98
0.00
2.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
2.2
—
1865.83
—
0
6
0
6
0.00
0.00
0.0
5.8
—
44.33
—
0
6
0
6
0.00
0.00
0.0
1.2
—
156.00
—
0
6
0
6
0.00
0.00
0.0
2.2
—
151.33
—
0
6
0
6
0.00
0.00
0.0
1.3
—
0.00
—
0
6
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
12
120
1.00
-0.00
2.1
1.6
—
—
—
0
0
6
67
0.89
-0.00
1.5
2.0
—
—
—
0
0
7
75
0.93
-0.00
1.7
2.5
—
17.72
—
0
6
0
9
0.00
-0.00
0.0
2.1
—
68.22
—
0
9
0
5
0.00
-0.00
0.0
3.4
—
20.50
—
0
5

Mortality – FinRegistry

↥

Association

Association between endpoint D3_THALASSAEMIA and mortality.

Females

Parameter HR [95% CI] p-value
D3_THALASSAEMIA 1.665 [1.07, 2.6] 0.025
Birth year 0.996 [0.99, 1.0] 0.362

During the follow-up period (1.1.1998 — 31.12.2019), 55 out of 893 females with D3_THALASSAEMIA died.

Males

Parameter HR [95% CI] p-value
D3_THALASSAEMIA 1.673 [1.12, 2.49] 0.011
Birth year 0.989 [0.98, 1.0] 0.034

During the follow-up period (1.1.1998 — 31.12.2019), 56 out of 775 males with D3_THALASSAEMIA died.

Mortality risk

Mortality risk for people of age

years, who have D3_THALASSAEMIA.

N-year risk Females Males
1 0.131% 0.315%
5 0.927% 2.064%
10 2.551% 5.115%
15 4.743% 9.437%
20 8.614% 16.314%

Relationships between endpoints

↥

Index endpoint: D3_THALASSAEMIA – Thalassaemia

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data